Arrowhead Pharmaceuticals strengthens plozasiran’s severe hypertriglyceridemia case with durable ACC.26 data
Arrowhead Pharmaceuticals’ plozasiran posted durable triglyceride reductions at ACC.26. Read what the long-term data could change next.
Pharma & Biotech